| pubmed-article:18772832 | pubmed:abstractText | Bevacizumab is a monoclonal antibody against vascular endothelial growth factor that is currently validated for treatment and has shown survival benefit in various cancers, particularly non-small cell lung cancer. However, a very specific toxicity profile has been observed with bevacizumab. This article presents data from the literature concerning hypertension and proteinuria, and provides recommendations for the management of these toxicities. | lld:pubmed |
